Related Experiment Video
Updated: May 8, 2026
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
Inhibitory effect of dsRNA TLR3 agonist in a rat hepatocellular carcinoma model
Yu-Yin Xu1, Li Chen, Jia-Ming Zhou
1Department of Pathological Anatomy, Nantong University, Nantong, Jiangsu 226001, P.R. China.
Abstract:
Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumor. Studies have demonstrated that the toll‑like receptor 3 (TLR3)/interferon pathway is inhibitory in cancer cell proliferation, suggesting that the activation of this pathway may have therapeutic potential. In the present study, the inhibitory effects of BM‑06, a double‑stranded (ds)RNA TLR3 agonist, against HCC were studied in vivo. Using a 2‑acetylaminofluorene-induced HCC rat model, histological examination and analysis of corresponding biomarkers following treatment with BM-06, showed a decrease in tumor growth and cell proliferation, and an increase in apoptosis compared with that in a phosphate‑buffered saline control group. In addition, the observed antitumor effect of BM‑06 in the HCC rat model was demonstrated to be superior to the known TLR3 agonist, polyinosinic-polycytidylic acid.
Insights
BM-06, a novel toll-like receptor 3 (TLR3) agonist, effectively inhibited hepatocellular carcinoma (HCC) growth in a rat model. This compound demonstrated superior efficacy compared to existing TLR3 agonists, indicating therapeutic potential for HCC treatment.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) is a prevalent malignancy.
- The toll-like receptor 3 (TLR3)/interferon pathway shows promise for inhibiting cancer cell proliferation.
- Targeting this pathway presents a potential therapeutic strategy for HCC.
Purpose of the Study:
- To investigate the in vivo inhibitory effects of BM-06, a double-stranded (ds)RNA TLR3 agonist, against hepatocellular carcinoma (HCC).
- To compare the efficacy of BM-06 with polyinosinic-polycytidylic acid, a known TLR3 agonist.
Main Methods:
- Utilized a 2-acetylaminofluorene-induced HCC rat model.
- Administered BM-06 and analyzed histological changes and biomarker expression.
- Compared outcomes with a phosphate-buffered saline control group and polyinosinic-polycytidylic acid treatment.
Main Results:
- BM-06 treatment led to a significant decrease in tumor growth and cancer cell proliferation in the HCC rat model.
- BM-06 treatment resulted in a notable increase in apoptosis within the tumor tissues.
- The antitumor effect of BM-06 was found to be superior to that of polyinosinic-polycytidylic acid.
Conclusions:
- BM-06 exhibits significant antitumor activity against hepatocellular carcinoma in vivo.
- The dsRNA TLR3 agonist BM-06 holds therapeutic potential for HCC treatment.
- BM-06 represents a promising agent for further investigation in HCC therapy.
